Drug Trial Radar · NCT03552471
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Last checked: Nov 20, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jul 12, 2018
Primary completion
Jun 24, 2022
Study completion Dec 19, 2022
Sponsor
- Lead sponsor
- Ohio State University Comprehensive Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ImmunoGen, Inc.; Clovis Oncology, Inc.
- First posted
- Jun 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.
Conditions
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- Folate Receptor Alpha Positive
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Uterine Corpus Carcinoma
- Recurrent Uterine Serous Carcinoma
- Recurrent Uterine Carcinosarcoma
- Platinum Resistant Ovarian Cancer
Interventions
Laboratory Biomarker AnalysisOther
Correlative studies
Mirvetuximab SoravtansineBiological
Given IV
Pharmacokinetic StudyOther
Correlative studies
Rucaparib CamsylateDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase II dose (RPTD) of mirvetuximab soravtansine and rucaparib camsylate in combinationTime frame: At the end of Cycle 1 (each cycle 15 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.